Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine

Neurology

Volumn 51, Issue 4, 1998, Pages 1219-1220

  Mandler, Raul N ^a   Ahmed, Waseem ^a   Dencoff, John E ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CUSHINGOID SYNDROME; FEMALE; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SLIT LAMP;

EID: 0031665071     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.4.1219     Document Type: Article

References (7)

1. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-168.
2. Oriordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-387.
3. Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology 1961;11:686-694.
4. Kurtzke JF. Clinical definition for multiple-sclerosis treatment trials. Ann Neurol 1994;36:S73-S79.
5. Luchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274.
6. Cock H, Mandler R, Ahmed W, Schapira AHV. Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 1997;62:85-87.
7. Mandler RN. Devic's neuromyelitis optica. Pathogenic characteristics and favorable response to immunotherapy in six acute patients. Presented at the 2nd annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS); San Diego, CA; September 28, 1997.